Context Therapeutics Inc (CNTX)

04:06 AM

What is William Blair’s Estimate for CNTX Q2 Earnings? - Defense World

04:06 AM

04:05 AM

Context Therapeutics Inc. (NASDAQ:CNTX) Stock Holdings Boosted by Geode Capital Management LLC - Defense World

04:05 AM

02:50 AM

Context Therapeutics’ (CNTX) Outperform Rating Reiterated at William Blair - Defense World

02:50 AM

01:57 AM

Context Therapeutics’ (CNTX) Buy Rating Reiterated at D. Boral Capital - Defense World

01:57 AM

May 01, 2025

Q1 Earnings Forecast for CNTX Issued By William Blair - Defense World

May 01, 2025

Apr 30, 2025

Context Therapeutics reports progress in cancer treatment By Investing.com - Investing.com India

Apr 30, 2025

Apr 30, 2025

Context Therapeutics (CNTX) Presents Promising Data on CT-95 at AACR 2025 | CNTX Stock News - GuruFocus

Apr 30, 2025

Apr 30, 2025

Context Therapeutics Presents Preclinical and Translational - GlobeNewswire

Apr 30, 2025

Apr 30, 2025

Breakthrough Cancer Treatment CT-95 Reveals Unique Binding Mechanism in Multiple Tumor Types - Stock Titan

Apr 30, 2025

Apr 24, 2025

Q1 Earnings Estimate for CNTX Issued By William Blair - Defense World

Apr 24, 2025

Apr 22, 2025

Context Therapeutics (NASDAQ:CNTX) Coverage Initiated by Analysts at William Blair - Defense World

Apr 22, 2025

Apr 21, 2025

William Blair Initiates Coverage of Context Therapeutics (CNTX) with Outperform Recommendation - Nasdaq

Apr 21, 2025

Apr 21, 2025

Bet on These 5 Top-Ranked Stocks With Rising P/E - NewsBreak: Local News & Alerts

Apr 21, 2025

Apr 21, 2025

William Blair starts Context Therapeutics stock with Outperform By Investing.com - Investing.com Canada

Apr 21, 2025

Apr 21, 2025

Stocks in play: Parkland Corporation - The Globe and Mail

Apr 21, 2025

Apr 19, 2025

Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results - ADVFN

Apr 19, 2025

Apr 19, 2025

Context Therapeutics Reports Full Year 2024 Operating and Financial Results - ADVFN

Apr 19, 2025

Apr 18, 2025

Context Therapeutics Inc. (NASDAQ:CNTX) Given Consensus Rating of “Buy” by Analysts - Defense World

Apr 18, 2025

Apr 18, 2025

Context Therapeutics Begins Phase 1 Trial of CT-95 Targeting Mesothelin-Expressing Cancers - MSN

Apr 18, 2025

Apr 11, 2025

D. Boral Capital Reaffirms Buy Rating for Context Therapeutics (NASDAQ:CNTX) - Defense World

Apr 11, 2025

Apr 10, 2025

Context Therapeutics to Showcase CT-95 Data at AACR 2025 - MSN

Apr 10, 2025

Apr 09, 2025

Context Swoons on CT-95 First Dose - Baystreet.ca

Apr 09, 2025

Apr 09, 2025

Context Therapeutics Begins Phase 1 Trial for CT-95 - TipRanks

Apr 09, 2025

Apr 09, 2025

Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95 - GlobeNewswire

Apr 09, 2025

Apr 09, 2025

Breakthrough Cancer Treatment Launches Trial: Targets 30% of All Cancer Types - Stock Titan

Apr 09, 2025

Apr 04, 2025

Zacks.com featured highlights include Context Therapeutics, Blue Bird, Dycom Industries and Leidos - Yahoo Finance

Apr 04, 2025

Apr 03, 2025

Bet on 4 Top-Ranked Stocks With Rising P/E for Solid Gains - Yahoo Finance

Apr 03, 2025

Apr 03, 2025

Carisma Therapeutics Focuses on Strategic Alternatives Amid Revised Operating Plan - MyChesCo

Apr 03, 2025

Apr 02, 2025

Context Therapeutics Announces Participation in Key Investor Conferences - MyChesCo

Apr 02, 2025

Apr 01, 2025

Context Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire

Apr 01, 2025

Apr 01, 2025

Context Therapeutics Unveils Packed Schedule: 4 Elite Healthcare Conferences Coming Up - Stock Titan

Apr 01, 2025

Apr 01, 2025

Context Therapeutics: 2024 Financial and Strategic Highlights - TipRanks

Apr 01, 2025

Mar 27, 2025

Context Therapeutics Inc. (NASDAQ:CNTX) Receives $6.17 Consensus PT from Brokerages - Defense World

Mar 27, 2025

Mar 26, 2025

Context Therapeutics Announces Poster Presentation at the - GlobeNewswire

Mar 26, 2025

Mar 26, 2025

Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025 - TradingView

Mar 26, 2025

Mar 26, 2025

Groundbreaking Cancer Drug Dosing Data: Context Therapeutics Reveals CT-95 Development at AACR 2025 - Stock Titan

Mar 26, 2025

Mar 24, 2025

JMP maintains $4 target on Context Therapeutics stock By Investing.com - Investing.com UK

Mar 24, 2025

Mar 24, 2025

What is HC Wainwright’s Forecast for CNTX Q3 Earnings? - Defense World

Mar 24, 2025

Mar 23, 2025

HC Wainwright Reiterates Buy Rating for Context Therapeutics (NASDAQ:CNTX) - Defense World

Mar 23, 2025

Mar 23, 2025

D. Boral Capital Reaffirms “Buy” Rating for Context Therapeutics (NASDAQ:CNTX) - Defense World

Mar 23, 2025

Mar 22, 2025

Companies Like Context Therapeutics (NASDAQ:CNTX) Are In A Position To Invest In Growth - Yahoo Finance

Mar 22, 2025

Mar 22, 2025

Context Therapeutics Reports 2024 Results and Outlines Clinical Advancements - MSN

Mar 22, 2025

Mar 21, 2025

Piper Sandler Sticks to Their Buy Rating for Context Therapeutics (CNTX) - The Globe and Mail

Mar 21, 2025

Mar 20, 2025

Context Therapeutics Inc. (CNTX) reports earnings - Quartz

Mar 20, 2025

Mar 20, 2025

Context Therapeutics Secures 3-Year Cash Runway with $94M War Chest, Expands Cancer Pipeline - StockTitan

Mar 20, 2025

Mar 20, 2025

Context Therapeutics Inc. Doses First Patient in Phase 1 Trial of CTIM-76 and Reports Strong Financial Position Transitioning into 2025 - Nasdaq

Mar 20, 2025

Mar 20, 2025

Context Therapeutics Inc. SEC 10-K Report - TradingView

Mar 20, 2025

Mar 17, 2025

CONTEXT THERAPEUTICS Earnings Preview: Recent $CNTX Insider Trading, Hedge Fund Activity, and More - Nasdaq

Mar 17, 2025

Mar 14, 2025

PHAXIAM THERAPEUTICS Announces the Launch of a Process to Find Buyers in the Context of its Receivership Procedure - Business Wire

Mar 14, 2025